Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Launched by INNOVENT BIOLOGICS (SUZHOU) CO. LTD. · May 30, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new medication called IBI362 to see how well it works and how safe it is for people with moderate to severe obesity. The study will involve different groups of participants, some receiving the medication and others receiving a placebo (a substance with no active medication). The goal is to learn more about the effects of IBI362 when taken by adults aged 18 to 55 who have a Body Mass Index (BMI) of 32.5 or higher and who have not lost more than 5% of their weight in the past three months while trying a diet and exercise plan.

To participate, individuals must be willing to follow specific guidelines, including diet and lifestyle changes, and they must meet certain health criteria. For example, they should not have serious health issues like diabetes or heart disease and should not have taken weight-related medications in the past three months. If eligible, participants can expect to receive careful monitoring throughout the trial to ensure their safety. This study is currently not recruiting participants, but it aims to better understand how IBI362 might help those struggling with obesity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The age at the time of screening is 18 to 55 years old (including both ends), male or female;
• • 2. BMI≥32.5 kg/m2 during screening;
• • 3. At the time of screening, after simple diet and exercise control for at least 12 weeks, the weight change was less than 5% \[(Maximum weight within 3 months before screening - minimum weight within 3 months before screening)/maximum weight within 3 months before screening ×100%, self-reported by the subjects\]
• • 4. Fertile subjects agreed to take the contraceptive measures stipulated in this protocol throughout the study and within 3 months after the last treatment. Female subjects with reproductive capacity must have negative pregnancy test results during screening. Female subjects should not breastfeed throughout the study and within 3 months after the last treatment;
• • 5. Voluntarily sign the informed consent form and be willing to strictly abide by the requirements and restrictions in the informed consent form and protocol throughout the research period, including but not limited to: diet, exercise, lifestyle management, planned injection of research drugs, keeping research diaries, and completing relevant questionnaires, etc;
• Exclusion Criteria:
• • 1. The investigator suspected that the subjects might be allergic to the study drug or component or have an allergic constitution;
• • 2. Use any of the following drugs or treatments within 3 months before screening including but not limited to GLP-1R, GIPR, GCGR, any drugs, Chinese herbal medicines, health supplements or meal replacements that have an impact on body weight, or participated in other clinical trials;
• • 3. There is a history or evidence of any of the following diseases before screening or at the time of screening including but not limited to diabetes, have received or plan to undergo bariatric surgery during the research period in the past, with retinopathy in the past or at the time of screening, secondary diseases or drugs lead to obesity, have a history of depression in the past or have a history of serious mental illness in the past, hypertension that has not been stably controlled at the time of screening after at least 4 weeks of antihypertensive drug treatment, a history of malignant tumors was present during the screening, heart disease, A 2A or 2B history or family history of medullary thyroid carcinoma and multiple endocrine adenomatosis (MEN) , history of acute and chronic pancreatitis, limb deformity or disability, have a history of suicidal tendencies or suicidal behaviors, etc according to the protocol.
• • 4. Any of the laboratory examination indicators meets the following standards during screening: serum calcitonin ≥20ng/L during screening, alanine aminotransferase ≥2.0×ULN and/or aspartate aminotransferase ≥2.0×ULN and/or total bilirubin ≥1.5×ULN and/or alkaline phosphatase ≥2.0×ULN, eGFR is less than 60 Ml/min/1.73 m2, abnormal thyroid function including FT3, FT4, or TSH, fasting triglycerides ≥5.64 mmol/L (500 mg/dl), blood amylase or lipase 1.0 x ULN;
• • 5. During the screening, the 12-lead electrocardiogram showed a heart rate of \<50 beats per minute or \>90 beats per minute;
• • 6. There were clinically significant ECGs abnormalities during the screening;
• • 7. History of other risk factors for tachycardia;
• • 8. The blood donation volume and/or blood loss volume within 3 months prior to screening is ≥400mL, or bone marrow donation has been performed, or there are anemia-related diseases such as hemoglobinopathy, hemolytic anemia, sickle cell anemia, etc., or hemoglobin.. 110g/ L (male) or 100g/L (females).
• • 9. The investigators believe that the subjects have any other factors that may affect the efficacy or safety evaluation of this study and are not suitable to participate in this study.